DCVC

Grove Biopharma is a biotechnology company offering a materials science solution to peptide therapeutic challenges, focused on the discovery and development of a novel class of “protein-like polymers” to treat significant unmet medical needs in chronic inflammatory and neurodegenerative diseases.

Latus Bio focuses on developing innovative gene therapy candidates using precision delivery to enhance the lives of patients. Latus identified proprietary AAV capsids for clinical use. The company plans to administer low doses of its product candidates, aiming to improve clinical safety and manufacturing.

Relation Therapeutics is a biotechnology company that focuses on humanizing drug discovery and development. It leverages human genetics and clinical omics data and utilizes patient-derived tissue samples with functional genomics interventional experiments to identify, validate, and prosecute therapeutic programs.

Elo Life Systems is a biotechnology company dedicated to enhancing human health and wellness through innovative food solutions. The company aims to connect food, agriculture, and health by addressing challenges related to agricultural productivity, nutritional needs, food security, and overall wellness. Elo employs advanced techniques such as precision breeding, genomics, data analytics, and machine learning to develop healthier food alternatives. By focusing on replacing sugar and artificial sweeteners, Elo strives to empower consumers to enjoy their favorite foods while leading healthier lives. Through strategic partnerships within the food systems value chain, the company seeks to create sustainable solutions that benefit both individuals and communities.

Totus Medicines specializes in developing innovative therapies to address previously untreatable diseases by harnessing advanced chemical biology techniques. The company utilizes a proprietary platform that enables high-throughput drug discovery, allowing it to screen billions of drug candidates against thousands of biological targets. This approach focuses on identifying effective molecules for traditionally challenging and undruggable targets, including those associated with cancer, Alzheimer's, infectious diseases, and the aging process. By converting genetic insights into viable therapeutic options, Totus Medicines aims to make a significant impact on the treatment landscape for various complex diseases.

Elo Life Systems is a biotechnology company dedicated to enhancing human health and wellness through innovative food solutions. The company aims to connect food, agriculture, and health by addressing challenges related to agricultural productivity, nutritional needs, food security, and overall wellness. Elo employs advanced techniques such as precision breeding, genomics, data analytics, and machine learning to develop healthier food alternatives. By focusing on replacing sugar and artificial sweeteners, Elo strives to empower consumers to enjoy their favorite foods while leading healthier lives. Through strategic partnerships within the food systems value chain, the company seeks to create sustainable solutions that benefit both individuals and communities.

evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniques we are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.

Nest Genomics is a lab-agnostic, comprehensive software solution for implementing genomic programs at scale.

Novome Biotechnologies, Inc. is a biotechnology company that focuses on engineering bacteria from the human gut to develop innovative treatments for chronic diseases. Its proprietary platform, which allows for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs), is designed to provide sustained therapeutic effects. Novome's lead preclinical program targets hyperoxaluria by developing a therapeutic strain of bacteria that degrades oxalate, thereby preventing kidney stone formation. The company aims to leverage its synthetic biology tools to expand its applications into additional health conditions, enhancing its ability to deliver precise therapeutic activities through engineered gut microbiota. Founded in 2015, Novome is headquartered in South San Francisco, California.

Relation Therapeutics is a biotechnology company that focuses on humanizing drug discovery and development. It leverages human genetics and clinical omics data and utilizes patient-derived tissue samples with functional genomics interventional experiments to identify, validate, and prosecute therapeutic programs.

Totus Medicines specializes in developing innovative therapies to address previously untreatable diseases by harnessing advanced chemical biology techniques. The company utilizes a proprietary platform that enables high-throughput drug discovery, allowing it to screen billions of drug candidates against thousands of biological targets. This approach focuses on identifying effective molecules for traditionally challenging and undruggable targets, including those associated with cancer, Alzheimer's, infectious diseases, and the aging process. By converting genetic insights into viable therapeutic options, Totus Medicines aims to make a significant impact on the treatment landscape for various complex diseases.

GenEdit Inc., founded in 2016 and based in Berkeley, California, focuses on advancing gene therapy through its innovative genome editing tools, particularly the CRISPR/Cas9 system. The company aims to address the challenges associated with gene therapy delivery by utilizing its proprietary NanoGalaxy™ platform, which systematically screens a library of nanoparticles to enhance the safety and efficiency of delivering genetic material to target tissues. GenEdit's technology is designed to facilitate therapeutic gene editing, offering a solution that is easier, faster, and more accurate than traditional methods. This positions GenEdit to potentially enable the treatment of previously incurable genetic diseases, significantly contributing to the future of non-viral, gene editing-based therapeutics.

evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniques we are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.

Empirico is a developer of an insights platform designed to turn biological insights from human genetics into new medicines.The company's platform uses biological datasets, human genetics, and programmable biology to power target discovery and development, enabling scientists to systematically generate, interrogate, and prioritize high-confidence therapeutic hypotheses.

Novome Biotechnologies, Inc. is a biotechnology company that focuses on engineering bacteria from the human gut to develop innovative treatments for chronic diseases. Its proprietary platform, which allows for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs), is designed to provide sustained therapeutic effects. Novome's lead preclinical program targets hyperoxaluria by developing a therapeutic strain of bacteria that degrades oxalate, thereby preventing kidney stone formation. The company aims to leverage its synthetic biology tools to expand its applications into additional health conditions, enhancing its ability to deliver precise therapeutic activities through engineered gut microbiota. Founded in 2015, Novome is headquartered in South San Francisco, California.

GenEdit Inc., founded in 2016 and based in Berkeley, California, focuses on advancing gene therapy through its innovative genome editing tools, particularly the CRISPR/Cas9 system. The company aims to address the challenges associated with gene therapy delivery by utilizing its proprietary NanoGalaxy™ platform, which systematically screens a library of nanoparticles to enhance the safety and efficiency of delivering genetic material to target tissues. GenEdit's technology is designed to facilitate therapeutic gene editing, offering a solution that is easier, faster, and more accurate than traditional methods. This positions GenEdit to potentially enable the treatment of previously incurable genetic diseases, significantly contributing to the future of non-viral, gene editing-based therapeutics.

evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniques we are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.

Asimov, Inc. is a biotechnology company that specializes in the design and development of genetically engineered therapeutics. Established in 2017 and based in Cambridge, Massachusetts, Asimov focuses on creating tools for programming living cells to enhance the design and manufacturing processes of biologics and gene therapies. The company's platform integrates synthetic biology, computer-aided design, and machine learning, allowing for the engineering of genetic circuits. Asimov's multidisciplinary team employs machine-learning algorithms that connect large-scale datasets with biological models, facilitating advancements in molecular manufacturing and therapeutic applications. The company is dedicated to optimizing the production of protein biologics, viral vectors, and cell and gene therapies.

Karius, Inc. is a life sciences company based in Redwood City, California, specializing in genomic insights for infectious diseases. The company offers a non-invasive blood test known as the Karius Test, which utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. By mapping the microbial landscape of each patient from a single blood draw, Karius aims to assist clinicians in making rapid and informed treatment decisions. The company's laboratory is CLIA-certified and CAP-accredited, ensuring high standards in clinical laboratory testing. Additionally, Karius provides laboratory services for pathogen biomarker detection tailored to biopharmaceutical companies.

Superfluid DX is focused on developing a translational science and data analysis platform that leverages cell-free mRNA to diagnose neurodegenerative and other diseases. The company utilizes innovative molecular diagnostics technology to extract genetic information from blood samples, specifically analyzing tissue-specific cell-free circulating RNA. This novel approach aims to enhance disease monitoring by enabling early detection of health issues and providing physicians with valuable insights into a patient's health status versus disease state. Through its advanced testing methods, Superfluid DX seeks to improve patient outcomes by facilitating timely interventions and better management of various medical conditions.

Sequence Bio is a biotechnology company focused on enhancing drug discovery and development by leveraging the genetic diversity found in isolated populations, particularly in Newfoundland. The company aims to improve the treatment of complex and inherited diseases through its genome therapy platform, which involves collecting DNA and health information from these unique populations. By understanding the genetic factors that contribute to disease, Sequence Bio seeks to identify better drug targets and create more effective medicines, ultimately addressing the high failure rate of drug candidates and expediting the delivery of much-needed therapies to patients.

Agenovir Corporation is focused on the research and development of antiviral therapeutics aimed at tackling diseases linked to latent or persistent viral reservoirs. The company employs advanced nucleases, including CRISPR/Cas9 technology, to precisely target and disrupt viral DNA. Established in 2014 and headquartered in South San Francisco, California, Agenovir operates as a subsidiary of Vir Biotechnology, Inc. Its innovative approach seeks to create a new class of nuclease-based antiviral therapeutics that can effectively eliminate pathogenic viral genomes, thereby providing healthcare providers with tools to treat patients suffering from severe and persistent viral infections.

Ginkgo Bioworks is a biotechnology company based in Boston, Massachusetts, founded in 2008. It specializes in biological engineering, designing and developing custom microbes and organisms for various applications. The company discovers and licenses molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, it offers probiotic bacteria aimed at protecting against infections and creates libraries of molecules for natural product discovery. Ginkgo Bioworks operates primarily in the markets of cultured ingredients, carbon mitigation, probiotics, and biosecurity. The biosecurity segment, which generates the majority of the company's revenue, provides data analytics and related services to organizations across diverse sectors, including food, agriculture, pharmaceuticals, and specialty chemicals.

One Codex is a data platform for applied microbial genomics, enabling new and valuable applications in clinical diagnostics, food safety, and biosecurity.

Ginkgo Bioworks is a biotechnology company based in Boston, Massachusetts, founded in 2008. It specializes in biological engineering, designing and developing custom microbes and organisms for various applications. The company discovers and licenses molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, it offers probiotic bacteria aimed at protecting against infections and creates libraries of molecules for natural product discovery. Ginkgo Bioworks operates primarily in the markets of cultured ingredients, carbon mitigation, probiotics, and biosecurity. The biosecurity segment, which generates the majority of the company's revenue, provides data analytics and related services to organizations across diverse sectors, including food, agriculture, pharmaceuticals, and specialty chemicals.

Karius, Inc. is a life sciences company based in Redwood City, California, specializing in genomic insights for infectious diseases. The company offers a non-invasive blood test known as the Karius Test, which utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. By mapping the microbial landscape of each patient from a single blood draw, Karius aims to assist clinicians in making rapid and informed treatment decisions. The company's laboratory is CLIA-certified and CAP-accredited, ensuring high standards in clinical laboratory testing. Additionally, Karius provides laboratory services for pathogen biomarker detection tailored to biopharmaceutical companies.

Omniome, Inc. is a biotechnology company based in San Diego, California, focused on developing a DNA sequencing platform that aims to deliver high accuracy in clinical sequencing. Founded in 2013, the company utilizes its proprietary Sequencing By Binding technology, which enhances nucleotide and DNA matching by harnessing the natural capabilities of polymerase. This innovative approach allows researchers to obtain accurate and rapid sequencing results at a lower cost, with the potential to significantly advance cancer diagnostics. Omniome is supported by prominent life sciences venture investors and is committed to becoming a trusted leader in the field of DNA sequencing.

Moleculo is a biotech company specializing in advanced DNA sequencing technologies aimed at enhancing genome analysis. The company has created a novel sequencing method that delivers long and accurate reads, significantly improving the efficiency and precision of various DNA sequencing applications. This innovation allows clients to explore a broader array of applications in genomics, thereby advancing research and development in the field.